Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-10-15
    E.g., 2018-10-15

Archive Search

5 results
12:00 AM, Jan 04, 2010  |  BioCentury | Finance

Restructuring watch

34 $34.6 2.60 9/30/09 $10.0 Cuts primarily in R&D; discontinued a Phase II trial of RP101
12:00 AM, Oct 12, 2009  |  BioCentury | Finance

Ebb & Flow

NASDAQ:SCLN) fell $0.42 (10%) to $3.73 on Monday after discontinuing a Phase II trial of RP101
BvdU ) to treat advanced pancreatic cancer on the recommendation of an independent DSMC. For …
12:00 AM, Jun 12, 2006  |  BioCentury | Finance

ASCO movers

SWX:ROCZ) (see B14). Avantogen (ASX:ACU) A$0.06 -A$0.05 -42% -$9.1 $10.9 Interim Ph II data for RP101
12:00 AM, Jun 06, 2005  |  BioCentury | Finance

Ebb & Flow

testing with its Pentrys to treat prostate cancer. The company also has a small molecule, RP101
12:00 AM, Feb 16, 2004  |  BioCentury | Finance

Ebb & Flow

Germany's RESprotect is looking for a partner to finance a Phase I/II trial of its RP101
Absent a partner, the company would look for E5-E10 million ($6.4-$12.7 million) in venture funding. RP101